Robert Archambault

494 total citations
31 papers, 299 citations indexed

About

Robert Archambault is a scholar working on Pulmonary and Respiratory Medicine, Endocrinology, Diabetes and Metabolism and Radiation. According to data from OpenAlex, Robert Archambault has authored 31 papers receiving a total of 299 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Pulmonary and Respiratory Medicine, 8 papers in Endocrinology, Diabetes and Metabolism and 6 papers in Radiation. Recurrent topics in Robert Archambault's work include Prostate Cancer Treatment and Research (27 papers), Prostate Cancer Diagnosis and Treatment (20 papers) and Hormonal and reproductive studies (8 papers). Robert Archambault is often cited by papers focused on Prostate Cancer Treatment and Research (27 papers), Prostate Cancer Diagnosis and Treatment (20 papers) and Hormonal and reproductive studies (8 papers). Robert Archambault collaborates with scholars based in Canada. Robert Archambault's co-authors include Boris Bahoric, Abdenour Nabid, Nathalie Carrier, F. Vincent, Luís Souhami, André‐Guy Martin, Céline Lemaire, Sylvie Vass, Marie Duclos and Rédouane Bettahar and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Urology and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Robert Archambault

28 papers receiving 294 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Robert Archambault Canada	9	276	87	40	38	33	31	299
Kenneth L. Zeitzer United States	10	255 0.9×	49 0.6×	36 0.9×	29 0.8×	42 1.3×	22	297
Rédouane Bettahar Canada	7	201 0.7×	90 1.0×	31 0.8×	35 0.9×	86 2.6×	16	275
M. L. Vázquez de la Torre Spain	6	266 1.0×	92 1.1×	26 0.7×	22 0.6×	26 0.8×	12	283
María Ángeles Cabeza Rodríguez Spain	6	290 1.1×	98 1.1×	22 0.6×	38 1.0×	40 1.2×	11	318
Carmen González San Segundo Spain	6	265 1.0×	87 1.0×	21 0.5×	24 0.6×	27 0.8×	26	288
A. Guerrero Spain	5	263 1.0×	91 1.0×	25 0.6×	18 0.5×	25 0.8×	16	279
Lennart Åström Sweden	9	247 0.9×	119 1.4×	18 0.5×	23 0.6×	32 1.0×	20	294
Alexander G. Balogh Canada	7	189 0.7×	36 0.4×	25 0.6×	30 0.8×	36 1.1×	10	223
Andrea Hiltz Canada	3	362 1.3×	68 0.8×	30 0.8×	88 2.3×	39 1.2×	4	407
Sara Khaksar United Kingdom	9	189 0.7×	67 0.8×	13 0.3×	16 0.4×	24 0.7×	22	230

Countries citing papers authored by Robert Archambault

Since Specialization

Citations

This map shows the geographic impact of Robert Archambault's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Archambault with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Archambault more than expected).

Fields of papers citing papers by Robert Archambault

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Archambault. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Archambault. The network helps show where Robert Archambault may publish in the future.

Co-authorship network of co-authors of Robert Archambault

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Archambault. A scholar is included among the top collaborators of Robert Archambault based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Archambault. Robert Archambault is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Nabid, Abdenour, Nathalie Carrier, André‐Guy Martin, et al.. (2025). Impact of testosterone recovery after androgen deprivation therapy on overall survival in patients with high-risk prostate cancer: Long-term data from a phase III trial.. Journal of Clinical Oncology. 43(5_suppl). 310–310.

Niazi, Tamim, Abdenour Nabid, Talía Malagón, et al.. (2024). Hypofractionated Dose Escalation Radiotherapy for High-Risk Prostate Cancer: the survival analysis of the Prostate Cancer Study-5 (PCS-5), a GROUQ-led phase III trial. European Urology. 87(3). 314–323. 3 indexed citations

Nabid, Abdenour, Nathalie Carrier, André‐Guy Martin, et al.. (2024). Quality of life and testosterone recovery after androgen deprivation therapy in high-risk prostate cancer patients: long-term data from a phase III trial. Quality of Life Research. 34(3). 725–737.

Nabid, Abdenour, Nathalie Carrier, Éric Vigneault, et al.. (2024). Testosterone recovery after androgen deprivation therapy in localised prostate cancer: Long-term data from two randomised trials. Radiotherapy and Oncology. 195. 110256–110256. 5 indexed citations

Niazi, Tamim, Abdenour Nabid, Talía Malagón, et al.. (2023). Hypofractionated, Dose Escalation Radiation Therapy for High-Risk Prostate Cancer: The Safety Analysis of the Prostate Cancer Study-5, a Groupe de Radio-Oncologie Génito-Urinaire de Quebec Led Phase 3 Trial. International Journal of Radiation Oncology*Biology*Physics. 118(1). 52–62. 9 indexed citations

Nabid, Abdenour, Nathalie Carrier, André‐Guy Martin, et al.. (2023). Quality of life comparison based on testosterone recovery after androgen deprivation therapy in patients cured from high-risk prostate cancer: Long term data from a phase III trial.. JCO Oncology Practice. 19(11_suppl). 333–333. 1 indexed citations

Niazi, Tamim, F. Vincent, M. Jolicoeur, et al.. (2023). Phase III Study of Hypofractionated, Dose Escalation Radiotherapy vs. Conventional Pelvic Radiation Therapy followed by High Dose Rate Brachytherapy Boost for High Risk Adenocarcinoma of the Prostate (PCS VI): Acute Toxicity Results. International Journal of Radiation Oncology*Biology*Physics. 117(2). S26–S26.

Tsui, James Man Git, Michael Jonathan Kucharczyk, Abdenour Nabid, et al.. (2021). The Clinical Significance of Bone Mineral Density Changes Following Long-Term Androgen Deprivation Therapy in Localized Prostate Cancer Patients. The Journal of Urology. 205(6). 1648–1654. 4 indexed citations

Nabid, Abdenour, Nathalie Carrier, Éric Vigneault, et al.. (2021). Optimizing Treatment in Intermediate-Risk Prostate Cancer: Secondary Analysis of a Randomized Phase 3 Trial. International Journal of Radiation Oncology*Biology*Physics. 111(3). 732–740. 6 indexed citations

10.

Nabid, Abdenour, Nathalie Carrier, Éric Vigneault, et al.. (2020). Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: A randomised phase III trial. European Journal of Cancer. 143. 64–74. 27 indexed citations

11.

Nabid, Abdenour, Nathalie Carrier, André‐Guy Martin, et al.. (2018). Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial. European Urology. 74(4). 432–441. 122 indexed citations

12.

Niazi, Tamim, Abdenour Nabid, Rédouane Bettahar, et al.. (2018). Hypofractionated, dose escalation radiotherapy for high-risk prostate cancer: The primary endpoint of a group led phase III trial. (PCS5).. Journal of Clinical Oncology. 36(6_suppl). 123–123. 6 indexed citations

13.

Nabid, Abdenour, Nathalie Carrier, Éric Vigneault, et al.. (2015). Place of short-term androgen deprivation therapy in intermediate-risk prostate cancer treated with radiotherapy: A phase III trial.. Journal of Clinical Oncology. 33(7_suppl). 5–5. 10 indexed citations

14.

Nabid, Abdenour, Nathalie Carrier, Éric Vigneault, et al.. (2015). A phase III trial of short-term androgen deprivation therapy in intermediate-risk prostate cancer treated with radiotherapy.. Journal of Clinical Oncology. 33(15_suppl). 5019–5019. 4 indexed citations

15.

Nabid, Abdenour, Nathalie Carrier, Éric Vigneault, et al.. (2015). Radiation Therapy With or Without Short-Term Androgen Deprivation Therapy in Intermediate-Risk Prostate Cancer: Results of a Phase 3 Trial. International Journal of Radiation Oncology*Biology*Physics. 94(1). 4–4. 4 indexed citations

16.

Nabid, Abdenour, Nathalie Carrier, André‐Guy Martin, et al.. (2014). Quality of Life in Patients with Testosterone Recovery after Long Term Androgen Deprivation Therapy for High Risk Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics. 90(1). S15–S16. 3 indexed citations

17.

Nabid, Abdenour, Nathalie Carrier, André‐Guy Martin, et al.. (2013). Duration of androgen deprivation therapy in high-risk prostate cancer: A randomized trial.. Journal of Clinical Oncology. 31(18_suppl). LBA4510–LBA4510. 15 indexed citations

18.

Nabid, Abdenour, Nathalie Carrier, André‐Guy Martin, et al.. (2013). High-risk prostate cancer treated with pelvic radiotherapy and 36 versus 18 months of androgen blockade: Results of a phase III randomized study.. Journal of Clinical Oncology. 31(6_suppl). 3–3. 21 indexed citations

19.

Nabid, Abdenour, Nathalie Carrier, André‐Guy Martin, et al.. (2011). 724 TESTOSTERONE RECOVERY IN PATIENTS WITH HIGH RISK PROSTATE CANCER TREATED WITH 36 VS 18 MONTHS OF ANDROGEN BLOCKADE AND PELVIC IRRADIATION. The Journal of Urology. 185(4S). 1 indexed citations

20.

Girardin, Giulia, et al.. (1969). [Thrombocytopenic purpura, a new clinical aspect of the congenital rubella syndrome].. PubMed. 101(6). 340–3. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact